SeekingAlpha · Feb 28, 2026
EB
NYSE · EBS
Emergent BioSolutions Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$6.81
Down-$0.41 (-5.68%)
Updated Nov 1, 2026, 9:24 PM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 633.13M
- P/E ratio
- 8.22
- Dividend yield
- 0.00%
- 52-week range
- $4.36 – $9.66
- Volume
- 754.44K
- Avg. volume
- 1.09M
Price performance · EBS
EBS price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
EBS closed at $6.81 after 20 trading sessions, down 5.94% for the selected period.
- Last close
- $6.81
- Period change
- -5.94%
- Period low
- $6.20
- Period high
- $7.24
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $7.11 | $7.305 | $6.76 | $6.81 | 754.44K |
| Oct 29, 2026 | $7.10 | $7.235 | $7.01 | $7.22 | 682.38K |
| Oct 28, 2026 | $6.63 | $7.09 | $6.555 | $7.09 | 800.82K |
| Oct 27, 2026 | $6.37 | $6.76 | $6.365 | $6.67 | 1.5M |
| Oct 26, 2026 | $6.28 | $6.40 | $6.14 | $6.34 | 485.44K |
| Oct 23, 2026 | $6.20 | $6.25 | $6.01 | $6.23 | 727.36K |
| Oct 22, 2026 | $6.20 | $6.36 | $6.09 | $6.23 | 838.56K |
| Oct 21, 2026 | $6.30 | $6.38 | $6.145 | $6.20 | 851.82K |
| Oct 20, 2026 | $6.34 | $6.34 | $6.0399 | $6.29 | 1.31M |
| Oct 19, 2026 | $6.40 | $6.5787 | $6.35 | $6.36 | 817.33K |
| Oct 16, 2026 | $6.64 | $6.73 | $6.1505 | $6.38 | 2.24M |
| Oct 15, 2026 | $6.96 | $7.225 | $6.84 | $7.18 | 654.82K |
| Oct 14, 2026 | $6.87 | $7.07 | $6.81 | $6.91 | 762.22K |
| Oct 13, 2026 | $6.95 | $7.07 | $6.85 | $6.91 | 576.16K |
| Oct 12, 2026 | $7.08 | $7.33 | $6.95 | $6.98 | 951.24K |
| Oct 9, 2026 | $6.73 | $7.06 | $6.595 | $7.06 | 850.96K |
| Oct 8, 2026 | $7.01 | $7.0119 | $6.785 | $6.81 | 1.15M |
| Oct 7, 2026 | $7.05 | $7.35 | $6.84 | $7.07 | 1.24M |
| Oct 6, 2026 | $7.16 | $7.27 | $6.75 | $6.95 | 1.86M |
| Oct 5, 2026 | $6.53 | $7.6496 | $6.45 | $7.24 | 2.35M |
Latest EBS news
The latest Smart Investors Daily articles mentioning EBS.
Stock researchCompany · Overview
Company
Market Activity
Research & News
EBS research
Overview
Company profile and research snapshot.
Company profile
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $51.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 21, 2026 | JP Morgan | Underweight | — |
| Aug 10, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 9, 2026 | HC Wainwright & Co. | Buy | — |
| Dec 16, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 27, 2026
Emergent BioSolutions shares are trading lower after the company reported worse-than-expected Q4 financial results and issued FY26 sales guidance below estimates.
SeekingAlpha · Feb 26, 2026
Emergent BioSolutions Inc. (EBS) Q4 2025 Earnings Call Prepared Remarks Transcript
Emergent BioSolutions Inc. (EBS) Q4 2025 Earnings Call February 26, 2026 5:00 PM ESTCompany ParticipantsFrank VargoJoseph Papa - CEO, President &...
ChartMill · Feb 26, 2026
Emergent BioSolutions Inc (NYSE:EBS) Shares Tumble on Weak Q4 Results and Cautious 2026 Outlook
Emergent BioSolutions' 2025 turnaround overshadowed by weak Q4 results and a cautious 2026 profit outlook, sending shares lower.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
